SHARE

Pharmacyte Biotech Inc (OTCMKTS:PMCB) advanced pancreatic cancer therapy of Cell-in-a-Box® capsules administered with low-doses of ifosfamide outperformed Eli Lilly and Co (NYSE:LLY)’s anti-cancer chemotherapy medication Gemzar® in early stage clinical studies when compared to historical statistics for gemcitabine in three major areas, one-year survivors, harmful side effects and median survival time.

The treatment also demonstrated better data in those same three areas in early stage studies than Celgene’s Abraxane® and gemcitabine, the existing “gold standard” offers pancreatic cancer patients. It now seems that Pharmacyte intends to follow the motto, “if you can beat them, join them.” Recently, the company reported that it has redesigned its forthcoming clinical study in pancreatic cancer to address a grave unmet medical need.

The details

Pharmacyte stated that the study is designed to develop an effective treatment for the patients suffering from advanced pancreatic cancer, who are not cured by the gold standard treatment. There are few treatment options available for such patients, and moreover such treatments are marginally effective in treating the disease.

Interestingly, a team of world famous oncologists are advising the company as to what is the best way to use Pharmacyte’s technology. The biotech’s treatment could play a significant part in the further treatment of patients.

The significance

It appears that Pharmacyte Biotech has been suggested that its therapy could work in conjunction with Abraxane plus gemcitabine as part of regimen. There is a chance that this new treatment can prove better compared to the current treatment of Abraxane plus gemcitabine. If Pharmacyte can achieve promising results from its clinical study, it can turn to be a center of attraction in the industry.

The company stated that it would be conducting its designed clinical study for the pain related with advanced pancreatic cancer as part of its upcoming clinical trial. It will significantly reduce the time and funds that company was to invest in this clinical trial.

PMCB

Pharmacyte Biotech Inc (OTCMKTS:PMCB) lost almost all the gains made in the previous day as it ended the last trading session with a major loss of 5.31%. The volume of 2.3 million was almost the same as the daily average of 2.2 million, not giving any strong clue about the next course of direction in the short term. The price action yesterday didn’t make the structure very strong and another day of decline may wipe out all the gains made this week. The long term chart attached shows the bearish momentum slowing down considerably but short term corrections may be expected to take place frequently.

LEAVE A REPLY